Interleukin-6 in Rheumatoid Arthritis

Interleukin-6 in Rheumatoid Arthritis

<b>: </b>The role of interleukin (IL)-6 in health and disease has been under a lot of scrutiny in recent years, particularly during the recent COVID-19 pandemic. The inflammatory pathways in which IL-6 is involved are also partly responsible of the development and progression of rheumato...

Full description

Bibliographic Details
Main Authors: Franco Pandolfi, Laura Franza, Valentina Carusi, Simona Altamura, Gloria Andriollo, Eleonora Nucera
Format: Article
Language:English
Published: MDPI AG 2020-07-01
Series:International Journal of Molecular Sciences
Subjects:
IL-6
rheumatoid arthritis
inflammation
Online Access:https://www.mdpi.com/1422-0067/21/15/5238
id doaj-f7c3d57f3aaf43c1b33cc285e8bf03d6
record_format Article
spelling doaj-f7c3d57f3aaf43c1b33cc285e8bf03d62020-11-25T03:26:33ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672020-07-01215238523810.3390/ijms21155238Interleukin-6 in Rheumatoid ArthritisFranco Pandolfi0Laura Franza1Valentina Carusi2Simona Altamura3Gloria Andriollo4Eleonora Nucera5Allergy and Clinical Immunology, Fondazione Policlinico Universitario A, Gemelli IRCCS, Catholic University, 00168, Rome, ItalyEmergency Medicine, Fondazione Policlinico Universitario A, Gemelli IRCCS, Università Cattolica del Sacro Cuore, 00168, Rome, ItalyAllergy and Clinical Immunology, Fondazione Policlinico Universitario A, Gemelli IRCCS, Catholic University, 00168, Rome, ItalyAllergy and Clinical Immunology, Fondazione Policlinico Universitario A, Gemelli IRCCS, Catholic University, 00168, Rome, ItalyAllergy and Clinical Immunology, Fondazione Policlinico Universitario A, Gemelli IRCCS, Catholic University, 00168, Rome, ItalyAllergy and Clinical Immunology, Fondazione Policlinico Universitario A, Gemelli IRCCS, Catholic University, 00168, Rome, Italy<b>: </b>The role of interleukin (IL)-6 in health and disease has been under a lot of scrutiny in recent years, particularly during the recent COVID-19 pandemic. The inflammatory pathways in which IL-6 is involved are also partly responsible of the development and progression of rheumatoid arthritis (RA), opening interesting perspectives in terms of therapy. Anti-IL-6 drugs are being used with variable degrees of success in other diseases and are being tested in RA. Results have been encouraging, particularly when anti-IL-6 has been used with other drugs, such as metothrexate (MTX). In this review we discuss the main immunologic aspects that make anti-IL-6 a good candidate in RA, but despite the main therapeutic options available to target IL-6, no gold standard treatment has been established so far.https://www.mdpi.com/1422-0067/21/15/5238IL-6rheumatoid arthritisinflammation
collection DOAJ
language English
format Article
sources DOAJ
author Franco Pandolfi
Laura Franza
Valentina Carusi
Simona Altamura
Gloria Andriollo
Eleonora Nucera
spellingShingle Franco Pandolfi
Laura Franza
Valentina Carusi
Simona Altamura
Gloria Andriollo
Eleonora Nucera
Interleukin-6 in Rheumatoid Arthritis
International Journal of Molecular Sciences
IL-6
rheumatoid arthritis
inflammation
author_facet Franco Pandolfi
Laura Franza
Valentina Carusi
Simona Altamura
Gloria Andriollo
Eleonora Nucera
author_sort Franco Pandolfi
title Interleukin-6 in Rheumatoid Arthritis
title_short Interleukin-6 in Rheumatoid Arthritis
title_full Interleukin-6 in Rheumatoid Arthritis
title_fullStr Interleukin-6 in Rheumatoid Arthritis
title_full_unstemmed Interleukin-6 in Rheumatoid Arthritis
title_sort interleukin-6 in rheumatoid arthritis
publisher MDPI AG
series International Journal of Molecular Sciences
issn 1661-6596
1422-0067
publishDate 2020-07-01
description <b>: </b>The role of interleukin (IL)-6 in health and disease has been under a lot of scrutiny in recent years, particularly during the recent COVID-19 pandemic. The inflammatory pathways in which IL-6 is involved are also partly responsible of the development and progression of rheumatoid arthritis (RA), opening interesting perspectives in terms of therapy. Anti-IL-6 drugs are being used with variable degrees of success in other diseases and are being tested in RA. Results have been encouraging, particularly when anti-IL-6 has been used with other drugs, such as metothrexate (MTX). In this review we discuss the main immunologic aspects that make anti-IL-6 a good candidate in RA, but despite the main therapeutic options available to target IL-6, no gold standard treatment has been established so far.
topic IL-6
rheumatoid arthritis
inflammation
url https://www.mdpi.com/1422-0067/21/15/5238
work_keys_str_mv AT francopandolfi interleukin6inrheumatoidarthritis
AT laurafranza interleukin6inrheumatoidarthritis
AT valentinacarusi interleukin6inrheumatoidarthritis
AT simonaaltamura interleukin6inrheumatoidarthritis
AT gloriaandriollo interleukin6inrheumatoidarthritis
AT eleonoranucera interleukin6inrheumatoidarthritis
_version_ 1724592054043934720

Similar Items